Molecule Details
| InChIKey | HNFMVVHMKGFCMB-UHFFFAOYSA-N |
|---|---|
| Compound Name | Miransertib |
| Canonical SMILES | Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 3 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 8.18 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB14982 |
|---|---|
| Drug Name | Miransertib |
| CAS Number | 1313881-70-7 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma). |
Categories: Amines Pyridines
Cross-references: CHEMBL4297188 ChemSpider: 57251282 PDB: 6S1 ZINC: ZINC000072315647